SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Pro

Company advances its internally developed drug discovery program targeting acute graft-versus-host d

EVGN

Related stories